Nurix Therapeutics
NRIX
66 hedge funds and large institutions have $1.11B invested in Nurix Therapeutics in 2020 Q3 according to their latest regulatory filings, with 66 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
86% more ownership
Funds ownership: 0% → 86% (+86%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PS
Peter Svennilson
|
+$170M |
| 2 |
TGI
TRV GP III
Boston,
Massachusetts
|
+$137M |
| 3 |
Wellington Management Group
Boston,
Massachusetts
|
+$84.9M |
| 4 |
RG
Redmile Group
San Francisco,
California
|
+$65.4M |
| 5 |
FCMI
Foresite Capital Management IV
Larkspur,
California
|
+$59.2M |
Top Sellers
NRIX Hedge Fund Activity: Q3 2020 in Review
66 of the 4,956 institutional investors tracked by Wall St. Rank reported a position in Nurix Therapeutics (NRIX) for Q3 2020, worth a combined $1.11B.
Buyers outnumbered sellers: 66 funds opened new NRIX positions and 0 closed out — a net gain of 66 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Peter Svennilson, opening a new position worth an estimated $170M.
- 66 institutional investors held Nurix Therapeutics (NRIX) as of Q3 2020, up from 0 in Q2 2020.
- Funds reported $1.11B of Nurix Therapeutics stock for Q3 2020.
- 66 funds opened new Nurix Therapeutics positions in Q3 2020 and 0 closed out, a net change of +66 holders.
- The largest Nurix Therapeutics buyer in Q3 2020 was Peter Svennilson, an estimated $170M added.
Based on aggregated 13F filings for Q3 2020.